Pulmatrix (PULM) Q1 2025 earnings summary

Executive summary

• Pulmatrix, a biopharma company focused on inhaled therapeutics using iSPERSE technology, is pausing development and seeking to monetize assets, including PUR3100, PUR1800, and PUR1900, pending a merger with Cullgen expected to close in June 2025.

• The merger will result in Cullgen shareholders owning 96.4% and Pulmatrix shareholders 3.6% of the combined company on a fully diluted basis.

• The combined company will focus on targeted protein degradation, with three degrader programs in Phase 1 trials for cancer and pain.

• Pulmatrix's future operations depend on the merger's completion; failure may lead to dissolution and liquidation.

Financial highlights

• No revenue was recognized for Q1 2025, compared to $5.9 million in Q1 2024, due to the completion of PUR1900 Phase 2b wind down.

• Net loss for Q1 2025 was $1.8 million, compared to net income of $0.8 million in Q1 2024.

• Research and development expenses dropped to less than $0.1 million in Q1 2025 from $3.5 million in Q1 2024, reflecting project wind-downs.

• General and administrative expenses increased to $1.8 million in Q1 2025 from $1.6 million in Q1 2024, mainly due to merger-related costs.

• Cash and cash equivalents as of March 31, 2025, were $7.7 million.

Outlook and guidance

• Existing cash and cash equivalents are expected to fund operations for at least the next 12 months or through the merger closing.

• Focus remains on completing the Cullgen merger and divesting clinical assets.

• Continued development of pipeline assets depends on securing additional funding or partnerships.

• The company anticipates continued operating losses if development resumes.